SG11202103851PA - Dry pharmaceutical composition for inhalation - Google Patents

Dry pharmaceutical composition for inhalation

Info

Publication number
SG11202103851PA
SG11202103851PA SG11202103851PA SG11202103851PA SG11202103851PA SG 11202103851P A SG11202103851P A SG 11202103851PA SG 11202103851P A SG11202103851P A SG 11202103851PA SG 11202103851P A SG11202103851P A SG 11202103851PA SG 11202103851P A SG11202103851P A SG 11202103851PA
Authority
SG
Singapore
Prior art keywords
inhalation
pharmaceutical composition
dry pharmaceutical
dry
composition
Prior art date
Application number
SG11202103851PA
Inventor
Martin Mueller
Irene Rossi
Gloria Spagnoli
Angelo Bolchi
Simone Ottonello
Ruggero Bettini
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of SG11202103851PA publication Critical patent/SG11202103851PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/544Mucosal route to the airways
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202103851PA 2018-10-18 2019-10-17 Dry pharmaceutical composition for inhalation SG11202103851PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18201253 2018-10-18
PCT/EP2019/078277 WO2020079185A1 (en) 2018-10-18 2019-10-17 Dry pharmaceutical composition for inhalation

Publications (1)

Publication Number Publication Date
SG11202103851PA true SG11202103851PA (en) 2021-05-28

Family

ID=64023943

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103851PA SG11202103851PA (en) 2018-10-18 2019-10-17 Dry pharmaceutical composition for inhalation

Country Status (7)

Country Link
US (1) US20210338575A1 (en)
EP (1) EP3866756A1 (en)
JP (1) JP2022505318A (en)
KR (1) KR20210079319A (en)
CN (1) CN113056258A (en)
SG (1) SG11202103851PA (en)
WO (1) WO2020079185A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948975A (en) * 2022-06-08 2022-08-30 郭雅图 Application of monophosphoryl lipid A in preparation of medicine for treating adult amblyopia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO2010003465A2 (en) 2008-07-11 2010-01-14 Universita' Degli Studi Di Parma A drug powder for inhalation administration and a process thereof
EP2199301A1 (en) 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof
BRPI1013895B1 (en) * 2009-04-10 2021-08-03 The Johns Hopkins University VIRUS-LIKE PARTICLE COMPOSITIONS (VLP) OF PAPILOMA AND CAPSOMERAL VIRUSES, METHOD OF PREPARATION THEREOF, VACCINE COMPRISING SUCH VLP COMPOSITION, CHIMERIC POLYPEPTIDE, KIT COMPRISING VLP REVERSE COMPOSITION, REFERRED TO WITH USES
ES2687288T3 (en) * 2012-03-02 2018-10-24 Institut National De La Santé Et De La Recherche Médicale (Inserm) Use of a tetrafunctional non-ionic amphiphilic block copolymer modified by glycosylation as an immune adjuvant
JP6375289B2 (en) * 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー Immune stimulating composition and method of use thereof
BR122019026637B1 (en) * 2013-07-18 2023-09-26 Mannkind Corporation PHARMACEUTICAL DRY POWDER FORMULATIONS AND METHOD FOR MANUFACTURING A DRY POWDER FORMULATION
JP6792294B2 (en) * 2015-05-29 2020-11-25 ダイナバックス テクノロジーズ コーポレイション Intrapulmonary administration of Toll-like receptor 9 agonists of polynucleotides for treating lung cancer
CN108350070B (en) * 2015-09-09 2022-01-28 诺华股份有限公司 Thymic Stromal Lymphopoietin (TSLP) -binding molecules and methods of use thereof
WO2017211886A1 (en) 2016-06-07 2017-12-14 Deutsches Krebsforschungszentrum Improvement of hpv l2 peptide immunogenicity

Also Published As

Publication number Publication date
US20210338575A1 (en) 2021-11-04
EP3866756A1 (en) 2021-08-25
CN113056258A (en) 2021-06-29
WO2020079185A1 (en) 2020-04-23
JP2022505318A (en) 2022-01-14
KR20210079319A (en) 2021-06-29

Similar Documents

Publication Publication Date Title
SG11202011761XA (en) Nicotine formulation
ZA201906613B (en) Pharmaceutical compositions for combination therapy
ZA201905510B (en) Pharmaceutical compositions for combination therapy
PL3107548T3 (en) Dry powder formulations for inhalation
GB201712159D0 (en) Pharmaceutical composition
ZA202006570B (en) Pharmaceutical formulations
GB201911517D0 (en) Pharmaceutical composition
GB201804548D0 (en) Pharmaceutical compositions
PL3179986T3 (en) Dry powder formulations for inhalation
EP3375443A4 (en) Pharmaceutical composition for treating respiratory diseases
GB201807053D0 (en) Pharmaceutical composition
SG11202103374TA (en) Pharmaceutical composition
IL268708B (en) Pharmaceutical compositions for combination therapy
PL3621682T3 (en) Dry powder inhaler
EP3727485C0 (en) Pharmaceutical composition
PT3632436T (en) Pharmaceutical composition comprising lenvatinib salts
SG11202103851PA (en) Dry pharmaceutical composition for inhalation
GB201808571D0 (en) Pharmaceutical compositions
EP3485888A4 (en) Medicinal composition for inhalation
EP3463378A4 (en) Dry powder formulations for inhalation
SG11202110315SA (en) Pharmaceutical composition
FI3908321T3 (en) Pharmaceutical composition
SG11202010792TA (en) Improved pharmaceutical formulations
PT3650024T (en) Pharmaceutical composition for nasal administration
GB201808567D0 (en) Pharmaceutical compositions